May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
HLA–A2 Expression in Uveal Melanoma: Implications for Adjuvant Immunotherapy
V. de Belvis; E. Midena; P. Radin; B. Boccassini; G. Lo Giudice
Author Affiliations & Notes
  • V. de Belvis
    Ophthalmology, University of Padova, Padova, Italy
  • E. Midena
    Ophthalmology, University of Padova, Padova, Italy
    Fondazione G.B. Bietti per l'Oftalmologia, Roma, Italy
  • P. Radin
    Ophthalmology, University of Padova, Padova, Italy
  • B. Boccassini
    Ophthalmology, University of Padova, Padova, Italy
  • G. Lo Giudice
    Ophthalmology, Conegliano Hospital, Conegliano, Italy
  • Footnotes
    Commercial Relationships  V. de Belvis, None; E. Midena, None; P. Radin, None; B. Boccassini, None; G. Lo Giudice, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 3414. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      HLA–A2 Expression in Uveal Melanoma: Implications for Adjuvant Immunotherapy
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      V. de Belvis, E. Midena, P. Radin, B. Boccassini, G. Lo Giudice; HLA–A2 Expression in Uveal Melanoma: Implications for Adjuvant Immunotherapy . Invest. Ophthalmol. Vis. Sci. 2005;46(13):3414.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Abstract: : Purpose: To evaluate HLA–A2 expression in a cohort of patients affected by uveal melanoma. Methods: A prospective study on 237 patients affected by choroidal and ciliary body melanoma was performed to quantify HLA–A2 expression. An analysis from the cytotoxic T lymphocytes (CTLs) in peripheral blood was made. Up regulation of HLA–A2 was related to: demographic characteristics, tumor dimensions, tumor recurrence and development of liver metastases. Results: Mean follow–up was 32 months (range 6–108 months). Mean large basal tumor diameter (LBD) was 8 mm (range 4–14 mm). HLA–A2 expression was positive in 110/237 cases (46%). HLA–A2 expression was negative in 127/237 cases (54%). Both groups were not statistically different as tumor characteristics (P>0.3, P>0.5). Eight patients HLA–A2+ (7.3%) developed liver metastases versus ten patients HLA A2– (7.9%). Conclusions: If HLA–A2 + is mandatory to treat patients affected by uveal melanoma with immunological adjuvant (i.e immunotherapy based on HLA class I restricted CTLs) more than 50% of patients are untreatable. Identification of more selective, individual cytogenetic prognostic markers is mandatory to improve patient selection for any adjuvant treatment.

Keywords: melanoma • immunomodulation/immunoregulation 
© 2005, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×